ProQR Therapeutics N.V.
PRQR · NASDAQ
Market closed$1.70$0.030000 (+1.80%)After hours $1.73 · +1.68%
Key statistics
Previous close$1.67
Open$1.66
Day high$1.76
Day low$1.62
52-week high$3.10
52-week low$1.33
Market cap179.03M
Volume676.12K
Average volume988.58K
P/E ratio-3.40
Forward P/E—
EPS-0.50
Dividend yield0.00%
Market context
Why it moved
PRQR shares moved higher today following news that CEO Daniel de Boer purchased a significant number of shares, signaling insider confidence in the company's outlook ahead of an upcoming earnings report.
What is happening
Recent company-specific developments and publisher coverage.
BioWorld News · July 18, 2026Proqr Therapeutics expands early-stage pipelineGuruFocus · July 14, 2026Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NVSeeking Alpha · July 4, 2026ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR)Simply Wall Street · July 2, 2026Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought €231k Of SharesGuruFocus · June 28, 2026ProQR Therapeutics (PRQR) Launches $50M Share Offering with Eli Lilly ParticipationStock Titan · June 25, 2026ProQR raises $50M as Lilly joins a $9.2M share buyQuiver Quantitative · June 25, 2026ProQR Therapeutics Reports Positive Phase 1 Target Engagement Data for AX-0810, Supporting Advancement of NTCP FranchiseGlobeNewswire · June 25, 2026ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement Benzinga · July 6, 2026ProQR Therapeutics Files Prospectus For Offering 3.03M Ordinary Shares On Behalf Of Selling Shareholder Benzinga · June 26, 2026Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3 Mt Newswire · June 26, 2026Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating Benzinga · June 25, 2026Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success Mt Newswire · June 25, 2026ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint Mt Newswire · June 25, 2026ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering Benzinga · June 25, 2026ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price Benzinga · June 25, 2026ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers